Cargando…
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
BACKGROUND: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown. METHODS: Influence of SLUG expression on cell proliferation and viability were investig...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418455/ https://www.ncbi.nlm.nih.gov/pubmed/28334729 http://dx.doi.org/10.1038/bjc.2017.82 |
_version_ | 1783234052434690048 |
---|---|
author | Pulkka, Olli-Pekka Nilsson, Bengt Sarlomo-Rikala, Maarit Reichardt, Peter Eriksson, Mikael Hall, Kirsten Sundby Wardelmann, Eva Vehtari, Aki Joensuu, Heikki Sihto, Harri |
author_facet | Pulkka, Olli-Pekka Nilsson, Bengt Sarlomo-Rikala, Maarit Reichardt, Peter Eriksson, Mikael Hall, Kirsten Sundby Wardelmann, Eva Vehtari, Aki Joensuu, Heikki Sihto, Harri |
author_sort | Pulkka, Olli-Pekka |
collection | PubMed |
description | BACKGROUND: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown. METHODS: Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib. RESULTS: SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both when patients were treated with surgery alone (HR=3.40, 95% CI=1.67–6.89, P=0.001) and when treated with surgery plus adjuvant imatinib (HR=1.83, 95% CI=1.29–2.60, P=0.001). CONCLUSIONS: GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling in GISTs. |
format | Online Article Text |
id | pubmed-5418455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-54184552017-05-18 SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour Pulkka, Olli-Pekka Nilsson, Bengt Sarlomo-Rikala, Maarit Reichardt, Peter Eriksson, Mikael Hall, Kirsten Sundby Wardelmann, Eva Vehtari, Aki Joensuu, Heikki Sihto, Harri Br J Cancer Translational Therapeutics BACKGROUND: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown. METHODS: Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib. RESULTS: SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both when patients were treated with surgery alone (HR=3.40, 95% CI=1.67–6.89, P=0.001) and when treated with surgery plus adjuvant imatinib (HR=1.83, 95% CI=1.29–2.60, P=0.001). CONCLUSIONS: GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling in GISTs. Nature Publishing Group 2017-04-25 2017-03-23 /pmc/articles/PMC5418455/ /pubmed/28334729 http://dx.doi.org/10.1038/bjc.2017.82 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Translational Therapeutics Pulkka, Olli-Pekka Nilsson, Bengt Sarlomo-Rikala, Maarit Reichardt, Peter Eriksson, Mikael Hall, Kirsten Sundby Wardelmann, Eva Vehtari, Aki Joensuu, Heikki Sihto, Harri SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title_full | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title_fullStr | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title_full_unstemmed | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title_short | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
title_sort | slug transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418455/ https://www.ncbi.nlm.nih.gov/pubmed/28334729 http://dx.doi.org/10.1038/bjc.2017.82 |
work_keys_str_mv | AT pulkkaollipekka slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT nilssonbengt slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT sarlomorikalamaarit slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT reichardtpeter slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT erikssonmikael slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT hallkirstensundby slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT wardelmanneva slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT vehtariaki slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT joensuuheikki slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour AT sihtoharri slugtranscriptionfactoraprosurvivalandprognosticfactoringastrointestinalstromaltumour |